Compare HYLN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | QURE |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2019 | 2013 |
| Metric | HYLN | QURE |
|---|---|---|
| Price | $5.06 | $48.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $5.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 6.6M | 2.3M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | $3,475,000.00 | ★ $13,107,000.00 |
| Revenue This Year | $197.93 | $126.12 |
| Revenue Next Year | $301.97 | $200.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | N/A |
| 52 Week Low | $1.31 | $8.73 |
| 52 Week High | $8.49 | $71.50 |
| Indicator | HYLN | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 76.25 |
| Support Level | $1.79 | $21.63 |
| Resistance Level | N/A | $60.70 |
| Average True Range (ATR) | 1.01 | 2.80 |
| MACD | -0.33 | 2.17 |
| Stochastic Oscillator | 4.10 | 93.21 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.